

*Risk Assessment and Pharmacoeconomics
in the Treatment of
Venous Thromboembolism*

This supplement to *The American Journal of Managed Care* includes 2 articles on the development of a venous thromboembolism risk assessment model and the economic benefits of early discharge of patients treated with low-molecular-weight heparin. The supplement has been peer reviewed by an expert in the field.

FACULTY

Gordon Cummins, MS

Sales Director
PharMetrics, Inc.
Watertown, Massachusetts

Daniel M. Huse, MA

Vice President and Chief
Scientific Officer
PharMetrics, Inc.
Watertown, Massachusetts

Mason W. Russell, MAPE

Vice President and
General Manager
ICSL Healthcare Research
Waltham, Massachusetts

**Douglas C. A. Taylor,
MBA**

Director, Analytic Services
ICSL Healthcare Research
Waltham, Massachusetts

DISCLOSURE STATEMENT

It is the policy of *The American Journal of Managed Care* to have all faculty who participate in programs sponsored by corporate organizations disclose any real or apparent conflicts of interest.

These participants have declared the following affiliations with corporate organizations.

■ **Mason W. Russell, MAPE**

Consultant To:

Aventis Pharmaceuticals Inc.
Pharmacia Corporation
Novartis Pharmaceuticals Corporation
Pfizer, Inc.
American Home Products, Inc.
Johnson and Johnson, Inc.

■ **Douglas C. A. Taylor, MBA**

Consultant To:

Aventis Pharmaceuticals Inc.
Pharmacia Corporation
Novartis Pharmaceuticals Corporation
Pfizer, Inc.
American Home Products, Inc.
Johnson and Johnson, Inc.

The participants listed below declare no financial arrangement or affiliation with any corporate organizations.

■ **Gordon Cummins, MS**

■ **Daniel M. Huse, MA**

Signed disclosures are on file at the offices of *The American Journal of Managed Care*, Jamesburg, New Jersey.

*Risk Assessment and Pharmacoeconomics
in the Treatment of
Venous Thromboembolism*

This program is supported by an educational grant from **Aventis Pharmaceuticals Inc.**



The contents of this supplement may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.